NCT04489589 (LIBERATE) is a Phase 4 clinical trial of Midodrine in Critical Illness, sponsored by University of Alberta.

Who is sponsoring NCT04489589?

NCT04489589 is sponsored by University of Alberta.

What drugs are being tested in NCT04489589?

Interventions in NCT04489589: Midodrine, Placebo.

What condition does NCT04489589 study?

NCT04489589 studies Critical Illness, Shock.

Is NCT04489589 still recruiting?

NCT04489589 is currently completed. Last updated 6 October 2023.

Last reviewed 2023-10-06 · How we verify

NCT04489589: LIBERATE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Midodrine for the Early Liberation of Vasopressor Support in the ICU

Completed Phase 4 Last updated 6 October 2023

What this trial tests

Phase 4 trial testing Midodrine in Critical Illness in 20 participants. Completed in 30 October 2022.

Timeline

22 March 2021

Primary endpoint
31 July 2022

30 October 2022

Quick facts

Lead sponsor	University of Alberta
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	20
Start date	22 March 2021
Primary completion	31 July 2022
Estimated completion	30 October 2022
Sites	1 location across Canada

Drugs / interventions tested

Midodrine — full drug profile →
Placebo

Conditions studied

Critical Illness — all drugs for Critical Illness →
Shock — all drugs for Shock →

Sponsor

University of Alberta

Who can join

18 and older, any sex, with Critical Illness or Shock. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Vasopressors are medications that are given intravenously to increase the blood pressure of patients with illnesses that cause dangerous blood pressure drops. When a doctor prescribes a vasopressor, they ask that the dose be adjusted to achieve a specific blood pressure. This kind of medical support with intravenous (IV) vasopressors are usual treatments in intensive care unit (ICU) settings. Oral vasopressors, such as midodrine, have been historically used to maintain blood pressure in non-critically ill patients. In this study, the investigators will be using midodrine to reduce the need for IV vasopressors as blood pressure improves during the stay in the ICU The LIBERATE pilot study will evaluate the role of midodrine for patients with low blood pressure in the ICU. The investigators are planning on enrolling up to 20 study participants to evaluate this question in the General Systems ICU at the University of Alberta Hospital.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Impact of Adjuvant Use of Midodrine to Intravenous Vasopressors: A Systematic Review and Meta-Analysis.
Al-Abdouh A, Haddadin S, Matta A, Jabri A, et al · · 2021 · cited 9× · PMID 34055408 · DOI 10.1155/2021/5588483
LIBERATE: a study protocol for midodrine for the early liberation from vasopressor support in the intensive care unit (LIBERATE): protocol for a randomized controlled trial.
Opgenorth D, Baig N, Fiest K, Karvellas C, et al · · 2022 · cited 4× · PMID 35246227 · DOI 10.1186/s13063-022-06115-0
Midodrine for the early liberation from vasopressor support in the ICU (LIBERATE): a feasibility study.
Kilcommons SJ, Hammal F, Opgenorth DL, Fiest KM, et al · · 2024 · cited 1× · PMID 39633467 · DOI 10.1186/s40814-024-01577-2

Verify or expand the search:

Other trials of Midodrine

Trials testing the same drug.

NCT07422948 — Efficacy and Safety of Early Initiation of Midodrine for Control and Prevention of Ascites and Its Related Complications · NA · not yet recruiting
NCT06319248 — MID-STEP (MIDodrine for Sepsis Treatment and Early vasoPressor Weaning) Trial · Phase 2 · recruiting
NCT06245590 — Evaluation of Low-dose Albumin and Midodrine Versus Midodrine Alone in Outcome of Recurrent Ascites in Patients With Dec · NA · unknown
NCT06213935 — Preoperative Oral Midodrine Versus Intraoperative Intravenous Norepinephrine in Preventing Post-spinal Anesthesia Hypote · NA · unknown
NCT06091345 — Midodrine Plus Albumin Versus Midodrine Alone to Prevent Cirrhosis Related Complications in Children With Cirrhosis and · NA · completed

Other recruiting trials for Critical Illness

Currently open trials in the same condition.

NCT06189924 — Exhaled Breath Condensate Analysis in Mechanically Ventilated Patients · recruiting
NCT07418242 — Prognostic Value of Novel Biomarkers on Adverse Renal Outcomes in High-Risk Cardiac Surgery Patients · recruiting
NCT07101640 — PK, Safety and Preliminary Efficacy Study of Montelukast in Critically Ill Infants With Developing Bronchopulmonary Dysp · Phase 1, PHASE2 · recruiting
NCT07177183 — Low Serum Creatinine as a Predictor of Prolonged Mechanical Ventilation and Weaning Failure · NA · recruiting
NCT07369258 — Clinical Application of Listening to Music to Prevent Delirium in the Intensive Care Unit · NA · recruiting

Other University of Alberta trials

Trials by the same sponsor.

NCT03240900 — Electrical Stimulation for Improving Postoperative Breast Sensation · NA · not yet recruiting
NCT04231760 — The Effect of Inhaled Nitric Oxide on Pulmonary Gas-exchange in COPD · Phase 1, PHASE2 · not yet recruiting
NCT06649604 — Reducing Pain From Retinal Laser With Vibrational Stimulation · NA · not yet recruiting
NCT06824077 — Reducing Days DELirious With DEXmedetomidine as Part of an Intensive Care Unit Sleep Promotion Bundle · EARLY_PHASE1 · not yet recruiting
NCT06920914 — Effects of Minimally vs. Ultra-Processed Diets on Potassium (K) Handling in CKD · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04489589 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Alberta
Last refreshed: 6 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04489589.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing